Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment

MT Newswires Live

03/04

Capricor Therapeutics (CAPR) said Tuesday it has received the US Food and Drug Administration's acceptance for review of its biologics license application for full approval of deramiocel to treat Duchenne muscular dystrophy cardiomyopathy.

The regulator's decision was based on the company's current cardiac data from its phase 2 HOPE-2 and HOPE-2 open label extension studies, Capricor added.

The regulator set Aug. 31 as the Prescription Drug User Fee Act target action date without any potential review issues at the moment, the company said.

Capricor's stock rose nearly 12% in recent Tuesday premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2516676908"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516676908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2516676908?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516676908","market":"us","top_or_hot":-1,"title":"Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment","media":"MT Newswires Live","content":"<html><body><p> Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CAPR) said Tuesday it has received the US Food and Drug Administration's acceptance for review of its biologics license application for full approval of deramiocel to treat Duchenne muscular dystrophy cardiomyopathy.</p><p>The regulator's decision was based on the company's current cardiac data from its phase 2 HOPE-2 and HOPE-2 open label extension studies, Capricor added.</p><p>The regulator set Aug. 31 as the Prescription Drug User Fee Act target action date without any potential review issues at the moment, the company said.</p><p>Capricor's stock rose nearly 12% in recent Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCapricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-04 21:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CAPR) said Tuesday it has received the US Food and Drug Administration's acceptance for review of its biologics license application for full approval of deramiocel to treat Duchenne muscular dystrophy cardiomyopathy.</p><p>The regulator's decision was based on the company's current cardiac data from its phase 2 HOPE-2 and HOPE-2 open label extension studies, Capricor added.</p><p>The regulator set Aug. 31 as the Prescription Drug User Fee Act target action date without any potential review issues at the moment, the company said.</p><p>Capricor's stock rose nearly 12% in recent Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2516676908","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516676908","pubTimestamp":1741094348,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Capricor Therapeutics  said Tuesday it has received the US Food and Drug Administration's acceptance for review of its biologics license application for full approval of deramiocel to treat Duchenne muscular dystrophy cardiomyopathy.The regulator's decision was based on the company's current cardiac data from its phase 2 HOPE-2 and HOPE-2 open label extension studies, Capricor added.The regulator set Aug. 31 as the Prescription Drug User Fee Act target action date without any potential review issues at the moment, the company said.Capricor's stock rose nearly 12% in recent Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CAPR":"Capricor Therapeutics Inc"},"translate_title":"Capricor Therapeutics获得FDA接受杜氏肌营养不良症治疗BLA审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":1},"content_text":"Capricor Therapeutics (CAPR) said Tuesday it has received the US Food and Drug Administration's acceptance for review of its biologics license application for full approval of deramiocel to treat Duchenne muscular dystrophy cardiomyopathy.The regulator's decision was based on the company's current cardiac data from its phase 2 HOPE-2 and HOPE-2 open label extension studies, Capricor added.The regulator set Aug. 31 as the Prescription Drug User Fee Act target action date without any potential review issues at the moment, the company said.Capricor's stock rose nearly 12% in recent Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}